Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Veitch Dallas P, Weiner Michael W, Aisen Paul S, Beckett Laurel A, DeCarli Charles, Green Robert C, Harvey Danielle, Jack Clifford R, Jagust William, Landau Susan M, Morris John C, Okonkwo Ozioma, Perrin Richard J, Petersen Ronald C, Rivera-Mindt Monica, Saykin Andrew J, Shaw Leslie M, Toga Arthur W, Tosun Duygu, Trojanowski John Q, Alzheimer's Disease Neuroimaging Initiative
Аннотация
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020.
METHODS: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion.
RESULTS: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity.
DISCUSSION: ADNI has had a profound impact in improving clinical trials for AD.
METHODS: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion.
RESULTS: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity.
DISCUSSION: ADNI has had a profound impact in improving clinical trials for AD.